Merrill maintains Genzyme at neutral

Genzyme Corp. was maintained by Merrill Lynch analyst Eric Ende at a neutral rating after the company reported fourth-quarter 2005 earnings per share $0.60, in line with guidance of $0.59-$0.61. Merrill maintained its 2006 and 2007 earnings-per-share estimates at $2.70 and $3.26 respectively. The analyst raised its total revenue estimate for 2006 to $3.21 billion from $3.14 billion, based in part on modestly higher Renagel and Fabrazyme estimates. Shares of the Cambridge, Mass., biotechnology company were up 68 cents, or 0.98%, at $69.80 on volume of 3,052,967 shares versus the three-month running average of 1,992,840 shares. (Nasdaq: GENZ)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.